TransMedics Group, Inc. (TMDX) Financials

NASDAQ:TMDX

Market Cap

1.91B

Total Revenue

93.46M

Gross Profit

65.27M

Operating Income

-31.44M

Net Income

-36.23M

Metric	2016	2017	2018	2019	2020	2021	2022
revenue	6,209,000	7,685,000	13,017,000	23,604,000	25,639,000	30,262,000	93,459,000
costOfRevenue	5,443,000	5,548,000	7,283,000	9,741,000	9,004,000	9,103,000	28,187,000
grossProfit	766,000	2,137,000	5,734,000	13,863,000	16,635,000	21,159,000	65,272,000
researchAndDevelopmentExpenses	15,637,000	14,957,000	13,656,000	19,870,000	18,831,000	22,304,000	26,812,000
sellingAndMarketingExpenses	--	674,000	1,023,000	--	931,000	--	18,209,000
generalAndAdministrativeExpenses	--	7,606,000	12,315,000	--	24,188,000	38,283,000	51,688,000
sellingGeneralAndAdministrativeExpenses	8,115,000	7,606,000	12,315,000	23,596,000	24,188,000	38,283,000	69,897,000
operatingExpenses	23,752,000	22,563,000	25,971,000	43,466,000	43,019,000	60,587,000	96,709,000
operatingIncome	-22,986,000	-20,426,000	-20,237,000	-29,603,000	-26,384,000	-39,428,000	-31,437,000
totalOtherIncomeExpensesNet	-100,000	707,000	-758,000	-3,904,000	-2,332,000	-4,751,000	-4,728,000
ebitda	-22,555,000	-19,248,000	-19,681,000	-28,813,000	-24,731,000	-40,305,000	-32,439,000
depreciationAndAmortization	426,000	630,000	769,000	790,000	1,653,000	-877,000	-1,002,000
interestIncome	--	--	--	--	--	--	--
interestExpense	979,000	1,072,000	2,720,000	4,353,000	3,985,000	3,874,000	3,726,000
incomeBeforeTax	-24,065,000	-20,791,000	-23,715,000	-33,507,000	-28,716,000	-44,179,000	-36,165,000
incomeTaxExpense	984,000	32,000	41,000	40,000	32,000	36,000	66,000
netIncome	-24,065,000	-20,823,000	-23,756,000	-33,547,000	-28,748,000	-44,215,000	-36,231,000
eps	-1.66	-1.44	-1.23	-2.36	-1.16	-1.6	-1.23
epsdiluted	-1.66	-1.44	-1.23	-2.36	-1.16	-1.6	-1.23
weightedAverageShsOut	14,478,118	14,478,118	19,246,097	14,204,787	24,702,764	27,616,839	29,556,633
weightedAverageShsOutDil	14,478,118	14,478,118	19,246,097	14,204,787	24,702,764	27,616,839	29,556,633
costAndExpenses	29,195,000	28,111,000	33,254,000	53,207,000	52,023,000	69,690,000	124,896,000
otherExpenses	5,000	548,000	-213,000	790,000	1,653,000	-877,000	-1,002,000

Key Facts

Industry

Medical Devices

Sector

Healthcare

Headquarters

Andover, MA, US

Website

transmedics.com

CEO

Dr. Waleed H. Hassanein M.D.

Employees

212

About the Company

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.